Inaktiver Wert

Andere Sprachen Ariad Pharmaceuticals, Inc.

Aktien

US04033A1007

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Ariad Pharmaceuticals : Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency	06.02.17
Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion	03.02.17
Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.	03.02.17
Ariad Pharmaceuticals : Acquisition May Not Be in the Best Interests of ARIA Shareholders	18.01.17
Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	13.01.17
Takeda Pharmaceutical : Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal	10.01.17
Takeda Pharmaceutical : rachète l'américain Ariad pour 5,2 milliards de dollars	09.01.17
Ariad Pharmaceuticals : Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion	09.01.17
Ariad Pharmaceuticals : Takeda to Acquire ARIAD Pharmaceuticals, Inc.	09.01.17
Ariad Pharmaceuticals : to Present at the 35th Annual J.P. Morgan Healthcare Conference	03.01.17
Ariad Pharmaceuticals : Investigational Medicine Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival in ALTA Study	07.12.16
Ariad Pharmaceuticals : Announces Data Presentations at American Society of Hematology Meeting	06.12.16
Ariad Pharmaceuticals : Presents Updated Brigatinib Data with 18.4 Months Median Intracranial Progression Free Survival (PFS) in ALK+ NSCLC Patients with CNS Metastases at the World Conference on Lung Cancer	05.12.16
Ariad Pharmaceuticals : to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer	02.12.16
Ariad Pharmaceuticals : Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial	29.11.16
Ariad Pharmaceuticals : Announces Data Presentations at the World Conference on Lung Cancer	16.11.16
Ariad Pharmaceuticals : Announces Launch of Inaugural ALK+ Day During Lung Cancer Awareness Month	14.11.16
Ariad Pharmaceuticals : Announces Phase 1/2 Trial Data on Investigational Drug Brigatinib Published in The Lancet Oncology	09.11.16
Ariad Pharmaceuticals : Reports Third Quarter 2016 Financial Results	07.11.16
Ariad Pharmaceuticals : to Present at the Jefferies 2016 London Healthcare Conference	02.11.16

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Ariad Pharmaceuticals, Inc.

Aktien

US04033A1007

Andere Sprachen

Filter